Trials / Completed
CompletedNCT00877149
Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B
A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to provide data of absence of inflammation in patient liver histology after long-term telbivudine treatment and thus help investigators to make a comprehensive judgment on treatment discontinuation in selected patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | telbivudine/LDT600 |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-04-01
- First posted
- 2009-04-07
- Last updated
- 2012-05-04
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00877149. Inclusion in this directory is not an endorsement.